Cargando…

P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

Detalles Bibliográficos
Autores principales:	Koehne, Guenther, Tomlinson, Benjamin, Suh, Hyung, Koura, Divya, Cho, Christina, Bambace, Nadia M, Bernard, Léa, Shah, Nirali N, Walter, Roland, Dipersio, John, Perales, Miguel-Angel, Loken, Michael R, Breitschwerdt, Kyle, Nath, Sritama, Raffel, Glen, Cooper, Brenda W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430557/ http://dx.doi.org/10.1097/01.HS9.0000972472.24418.bc

Ejemplares similares

Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019)

Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
por: Pautas, Cécile, et al.
Publicado: (2021)

Early Respiratory Viral Acquisition after Allogeneic Hematopoietic Cell Transplant (HCT)
por: Boonyaratanakornkit, Jim, et al.
Publicado: (2019)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Fatobene, Giancarlo, et al.
Publicado: (2021)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients
por: Foolad, Farnaz, et al.
Publicado: (2017)

1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Baumrin, Emily, et al.
Publicado: (2018)

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy
por: Infante, Maria Stefania, et al.
Publicado: (2022)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
por: Zaytsev, Daniil, et al.
Publicado: (2020)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Human Coronavirus (HCOV) and Rhinovirus (HRHV) Infection among Hematopoietic Stem Cell Transplantation (HCT) Recipients
por: Milano, F., et al.
Publicado: (2009)

1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019)

Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT
por: Campbell, Angela P., et al.
Publicado: (2010)

1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience
por: Zavras, Phaedon D, et al.
Publicado: (2019)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
por: Kurimoto, M, et al.
Publicado: (2013)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

1560. Clinical Presentation of BK Virus-Associated Hemorrhagic Cystitis (HC) After Hematopoietic Cell Transplantation (HCT)
por: Imlay, Hannah, et al.
Publicado: (2018)

Impact of Pretransplant Respiratory Virus Detection through Universal Screening in Children Undergoing Hematopoietic Cell Transplantation (HCT)
por: Kim, Yae-Jean, et al.
Publicado: (2017)

An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients
por: Skeens, Micah, et al.
Publicado: (2022)

Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience
por: Srinivasan, Krithika, et al.
Publicado: (2022)

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
por: Geerlinks, Ashley V., et al.
Publicado: (2023)

Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients
por: Neely, Jessica A., et al.
Publicado: (2019)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
por: Mamolo, Carla, et al.
Publicado: (2020)

Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
por: Hååg, Petra, et al.
Publicado: (2022)

Decisions in HCT and wine-making
por: McCann, Shaun
Publicado: (2020)

Biomarkers for Allogeneic HCT Outcomes
por: Adom, Djamilatou, et al.
Publicado: (2020)

COVID-19, HCT and wine
por: McCann, Shaun R.
Publicado: (2020)

The effect of weather on HCT and vines
por: McCann, Shaun R.
Publicado: (2021)

Self Collection of Nasal Swabs for Diagnosis of Respiratory Viruses in Immunocompetent Volunteers and Hematopoietic Stem Cell Transplant (HCT) Recipients
por: Campbell, A.P., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bpt9qaghp0hcombam4j7b9ep3k